Assay
|
PROMONITOR® is a test that allows the circulating level of anti-TNFα biologics in plasma to be accurately determined and secondly detects and measures the levels of any patient-produced antibodies targeting the drug itself. Proteomika has developed CE-marked kits for monitoring patients treated with infliximab (Remicade®), adalimumab (Humira®), etanercept (Enbrel®) and rituximab (Mabthera®). Please go to the Order section for a detailed list of local authorized distributors in each territory.
Proteomika also offers clinical analysis testing for all the drugs and anti-drug antibodies. PROMONITOR® allows the circulating levels of each drug and any immune response triggered in the patient by the treatment to be measured extremely accurately thus allowing better clinical management of patients.
|
 |
The PROMONITOR® family of tests has been developed using ELISA technology allowing rapid turn-around times for result reporting. All assays have been extensively validated and are performed under GLP conditions in ISO13485 accredited facilities under GMPs.
| Analysis | Sample |
Required volume |
| Circulating levels of infliximab and antibodies against infliximab | Serum | 300 µl |
| Circulating levels of adalimumab and antibodies against adalimumab | Serum | 300 µl |
| Circulating levels of etanercept and antibodies against etanercept | Serum |
300 µl |
| Circulating levels of rituximab and antibodies against rituximab | Serum | 300 µl |